Search

Your search keyword '"Hengstler, Jan G."' showing total 513 results
Start Over Author "Hengstler, Jan G." Search Limiters Available in Library Collection
513 results on '"Hengstler, Jan G."'

2. Basal MET phosphorylation is an indicator of hepatocyte dysregulation in liver disease

Author

Burbano de Lara, Sebastian, Kemmer, Svenja, Biermayer, Ina, Feiler, Svenja, Vlasov, Artyom, D’Alessandro, Lorenza A, Helm, Barbara, Mölders, Christina, Dieter, Yannik, Ghallab, Ahmed, Hengstler, Jan G, Körner, Christiane, Matz-Soja, Madlen, Götz, Christina, Damm, Georg, Hoffmann, Katrin, Seehofer, Daniel, Berg, Thomas, Schilling, Marcel, Timmer, Jens, and Klingmüller, Ursula

Published
2024
Full Text
View/download PDF

5. Alterations in the hepatocyte epigenetic landscape in steatosis

Author

Maji, Ranjan Kumar, Czepukojc, Beate, Scherer, Michael, Tierling, Sascha, Cadenas, Cristina, Gianmoena, Kathrin, Gasparoni, Nina, Nordström, Karl, Gasparoni, Gilles, Laggai, Stephan, Yang, Xinyi, Sinha, Anupam, Ebert, Peter, Falk-Paulsen, Maren, Kinkley, Sarah, Hoppstädter, Jessica, Chung, Ho-Ryun, Rosenstiel, Philip, Hengstler, Jan G., Walter, Jörn, Schulz, Marcel H., Kessler, Sonja M., and Kiemer, Alexandra K.

Published
2023
Full Text
View/download PDF

6. Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth

Author

Keller, Magdalena, Rohlf, Katharina, Glotzbach, Annika, Leonhardt, Gregor, Lüke, Simon, Derksen, Katharina, Demirci, Özlem, Göçener, Defne, AlWahsh, Mohammad, Lambert, Jörg, Lindskog, Cecilia, Schmidt, Marcus, Brenner, Walburgis, Baumann, Matthias, Zent, Eldar, Zischinsky, Mia-Lisa, Hellwig, Birte, Madjar, Katrin, Rahnenführer, Jörg, Overbeck, Nina, Reinders, Jörg, Cadenas, Cristina, Hengstler, Jan G., Edlund, Karolina, and Marchan, Rosemarie

Published
2023
Full Text
View/download PDF

8. Model predicts fundamental role of biomechanical control of cell cycle progression during liver regeneration after partial hepatectomy

Author

Hoehme, Stefan, Gebhardt, Rolf, Hengstler, Jan G., and Drasdo, Dirk

Subjects
Quantitative Biology - Tissues and Organs, Quantitative Biology - Cell Behavior
Abstract

Partial hepatectomy (PHx) is a surgical intervention where a part of the liver is removed. Due to its extraordinary capacity to regenerate, the liver is able to regenerate about two-thirds of its mass within a few weeks. Nevertheless, in some patients regeneration fails. Understanding the principles and limitations underlying regeneration may permit to control this process and prospectively improve the regeneration. Here, we established a simulation model to mimic the process of regeneration in the liver lobe of a mouse. This model represents each hepatocyte individually and builds upon a previous computational model of regeneration of drug induced damage in a single liver lobule. The present study simulates entire liver lobes that consist of hundreds to thousands of lobules. It accounts for biomechanical control of cell cycle progression (Biomechanical Growth Control), which has not been considered in that previous work. The model reproduced the available experimental observations only if BGC was taken into account. Interestingly, the model predicted that BGC minimizes the number of proliferating neighbor cells of a proliferating cell resulting in a checkerboard-like proliferation pattern. Moreover, the model predicted different cell proliferation patterns in pigs and mice that corresponded to data obtained from regenerating tissue of the two species. In conclusion, the here established model suggest that biomechanical control mechanisms may play a significant role in liver regeneration after PHx.

Published
2020

9. Tolerance of repeated toxic injuries of murine livers is associated with steatosis and inflammation

Author

Hammad, Seddik, Ogris, Christoph, Othman, Amnah, Erdoesi, Pia, Schmidt-Heck, Wolfgang, Biermayer, Ina, Helm, Barbara, Gao, Yan, Piorońska, Weronika, Holland, Christian H., D’Alessandro, Lorenza A., de la Torre, Carolina, Sticht, Carsten, Al Aoua, Sherin, Theis, Fabian J., Bantel, Heike, Ebert, Matthias P., Klingmüller, Ursula, Hengstler, Jan G., Dooley, Steven, and Mueller, Nikola S.

Published
2023
Full Text
View/download PDF

11. Sublethal necroptosis signaling promotes inflammation and liver cancer

Author

Vucur, Mihael, Ghallab, Ahmed, Schneider, Anne T., Adili, Arlind, Cheng, Mingbo, Castoldi, Mirco, Singer, Michael T., Büttner, Veronika, Keysberg, Leonie S., Küsgens, Lena, Kohlhepp, Marlene, Görg, Boris, Gallage, Suchira, Barragan Avila, Jose Efren, Unger, Kristian, Kordes, Claus, Leblond, Anne-Laure, Albrecht, Wiebke, Loosen, Sven H., Lohr, Carolin, Jördens, Markus S., Babler, Anne, Hayat, Sikander, Schumacher, David, Koenen, Maria T., Govaere, Olivier, Boekschoten, Mark V., Jörs, Simone, Villacorta-Martin, Carlos, Mazzaferro, Vincenzo, Llovet, Josep M., Weiskirchen, Ralf, Kather, Jakob N., Starlinger, Patrick, Trauner, Michael, Luedde, Mark, Heij, Lara R., Neumann, Ulf P., Keitel, Verena, Bode, Johannes G., Schneider, Rebekka K., Tacke, Frank, Levkau, Bodo, Lammers, Twan, Fluegen, Georg, Alexandrov, Theodore, Collins, Amy L., Nelson, Glyn, Oakley, Fiona, Mann, Derek A., Roderburg, Christoph, Longerich, Thomas, Weber, Achim, Villanueva, Augusto, Samson, Andre L., Murphy, James M., Kramann, Rafael, Geisler, Fabian, Costa, Ivan G., Hengstler, Jan G., Heikenwalder, Mathias, and Luedde, Tom

Published
2023
Full Text
View/download PDF

12. Evaluation of the genotoxic potential of acrylamide: Arguments for the derivation of a tolerable daily intake (TDI value)

Author

Guth, Sabine, Baum, Matthias, Cartus, Alexander T., Diel, Patrick, Engel, Karl-Heinz, Engeli, Barbara, Epe, Bernd, Grune, Tilman, Haller, Dirk, Heinz, Volker, Hellwig, Michael, Hengstler, Jan G., Henle, Thomas, Humpf, Hans-Ulrich, Jäger, Henry, Joost, Hans-Georg, Kulling, Sabine E., Lachenmeier, Dirk W., Lampen, Alfonso, Leist, Marcel, Mally, Angela, Marko, Doris, Nöthlings, Ute, Röhrdanz, Elke, Roth, Angelika, Spranger, Joachim, Stadler, Richard, Steinberg, Pablo, Vieths, Stefan, Wätjen, Wim, and Eisenbrand, Gerhard

Published
2023
Full Text
View/download PDF

16. Intestinal Dysbiosis Amplifies Acetaminophen-Induced Acute Liver Injury

Author

Schneider, Kai Markus, Elfers, Carsten, Ghallab, Ahmed, Schneider, Carolin Victoria, Galvez, Eric J.C., Mohs, Antje, Gui, Wenfang, Candels, Lena Susanna, Wirtz, Theresa Hildegard, Zuehlke, Sebastian, Spiteller, Michael, Myllys, Maiju, Roulet, Alain, Ouzerdine, Amirouche, Lelouvier, Benjamin, Kilic, Konrad, Liao, Lijun, Nier, Anika, Latz, Eicke, Bergheim, Ina, Thaiss, Christoph A., Hengstler, Jan G., Strowig, Till, and Trautwein, Christian

Published
2021
Full Text
View/download PDF

17. TiQuant: Software for tissue analysis, quantification and surface reconstruction

Author

Friebel, Adrian, Neitsch, Johannes, Johann, Tim, Hammad, Seddik, Hengstler, Jan G., Drasdo, Dirk, and Hoehme, Stefan

Subjects
Computer Science - Computational Engineering, Finance, and Science, Computer Science - Graphics, Quantitative Biology - Tissues and Organs
Abstract

Motivation: TiQuant is a modular software tool for efficient quantification of biological tissues based on volume data obtained by biomedical image modalities. It includes a number of versatile image and volume processing chains tailored to the analysis of different tissue types which have been experimentally verified. TiQuant implements a novel method for the reconstruction of three-dimensional surfaces of biological systems, data that often cannot be obtained experimentally but which is of utmost importance for tissue modelling in systems biology. Availability: TiQuant is freely available for non-commercial use at msysbio.com/tiquant. Windows, OSX and Linux are supported., Comment: 6 pages, 4 figures

Published
2014

18. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry

Author

Figueroa, Jonine D, Middlebrooks, Candace D, Banday, A Rouf, Ye, Yuanqing, Garcia-Closas, Montserrat, Chatterjee, Nilanjan, Koutros, Stella, Kiemeney, Lambertus A, Rafnar, Thorunn, Bishop, Timothy, Furberg, Helena, Matullo, Giuseppe, Golka, Klaus, Gago-Dominguez, Manuela, Taylor, Jack A, Fletcher, Tony, Siddiq, Afshan, Cortessis, Victoria K, Kooperberg, Charles, Cussenot, Olivier, Benhamou, Simone, Prescott, Jennifer, Porru, Stefano, Dinney, Colin P, Malats, Núria, Baris, Dalsu, Purdue, Mark P, Jacobs, Eric J, Albanes, Demetrius, Wang, Zhaoming, Chung, Charles C, Vermeulen, Sita H, Aben, Katja K, Galesloot, Tessel E, Thorleifsson, Gudmar, Sulem, Patrick, Stefansson, Kari, Kiltie, Anne E, Harland, Mark, Teo, Mark, Offit, Kenneth, Vijai, Joseph, Bajorin, Dean, Kopp, Ryan, Fiorito, Giovanni, Guarrera, Simonetta, Sacerdote, Carlotta, Selinski, Silvia, Hengstler, Jan G, Gerullis, Holger, Ovsiannikov, Daniel, Blaszkewicz, Meinolf, Castelao, Jose Esteban, Calaza, Manuel, Martinez, Maria Elena, Cordeiro, Patricia, Xu, Zongli, Panduri, Vijayalakshmi, Kumar, Rajiv, Gurzau, Eugene, Koppova, Kvetoslava, Bueno-De-Mesquita, H Bas, Ljungberg, Börje, Clavel-Chapelon, Françoise, Weiderpass, Elisabete, Krogh, Vittorio, Dorronsoro, Miren, Travis, Ruth C, Tjønneland, Anne, Brennan, Paul, Chang-Claude, Jenny, Riboli, Elio, Conti, David, Stern, Marianna C, Pike, Malcolm C, Van Den Berg, David, Yuan, Jian-Min, Hohensee, Chancellor, Jeppson, Rebecca P, Cancel-Tassin, Geraldine, Roupret, Morgan, Comperat, Eva, Turman, Constance, De Vivo, Immaculata, Giovannucci, Edward, Hunter, David J, Kraft, Peter, Lindstrom, Sara, Carta, Angela, Pavanello, Sofia, Arici, Cecilia, Mastrangelo, Giuseppe, Kamat, Ashish M, Zhang, Liren, Gong, Yilei, Pu, Xia, Hutchinson, Amy, Burdett, Laurie, Wheeler, William A, and Karagas, Margaret R

Subjects
Cancer, Prevention, Human Genome, Genetics, Biotechnology, Urologic Diseases, Aetiology, 2.1 Biological and endogenous factors, Biomarkers, Tumor, Case-Control Studies, Chromosomes, Human, Pair 13, Chromosomes, Human, Pair 20, Female, Genetic Association Studies, Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Linkage Disequilibrium, Male, Polymorphism, Single Nucleotide, Risk Factors, Urinary Bladder Neoplasms, White People, Biological Sciences, Medical and Health Sciences, Genetics & Heredity
Abstract

Candidate gene and genome-wide association studies (GWAS) have identified 15 independent genomic regions associated with bladder cancer risk. In search for additional susceptibility variants, we followed up on four promising single-nucleotide polymorphisms (SNPs) that had not achieved genome-wide significance in 6911 cases and 11 814 controls (rs6104690, rs4510656, rs5003154 and rs4907479, P < 1 × 10(-6)), using additional data from existing GWAS datasets and targeted genotyping for studies that did not have GWAS data. In a combined analysis, which included data on up to 15 058 cases and 286 270 controls, two SNPs achieved genome-wide statistical significance: rs6104690 in a gene desert at 20p12.2 (P = 2.19 × 10(-11)) and rs4907479 within the MCF2L gene at 13q34 (P = 3.3 × 10(-10)). Imputation and fine-mapping analyses were performed in these two regions for a subset of 5551 bladder cancer cases and 10 242 controls. Analyses at the 13q34 region suggest a single signal marked by rs4907479. In contrast, we detected two signals in the 20p12.2 region-the first signal is marked by rs6104690, and the second signal is marked by two moderately correlated SNPs (r(2) = 0.53), rs6108803 and the previously reported rs62185668. The second 20p12.2 signal is more strongly associated with the risk of muscle-invasive (T2-T4 stage) compared with non-muscle-invasive (Ta, T1 stage) bladder cancer (case-case P ≤ 0.02 for both rs62185668 and rs6108803). Functional analyses are needed to explore the biological mechanisms underlying these novel genetic associations with risk for bladder cancer.

Published
2016

19. Increased sinusoidal export of drug glucuronides is a compensative mechanism in liver cirrhosis of mice

Author

Fendt, Rebekka, primary, Ghallab, Ahmed, additional, Myllys, Maiju, additional, Hofmann, Ute, additional, Hassan, Reham, additional, Hobloss, Zaynab, additional, González, Daniela, additional, Brackhagen, Lisa, additional, Marchan, Rosemarie, additional, Edlund, Karolina, additional, Seddek, Abdel-Latif, additional, Abdelmageed, Noha, additional, Blank, Lars M., additional, Schlender, Jan-Frederik, additional, Holland, Christian H., additional, Hengstler, Jan G., additional, and Kuepfer, Lars, additional

Published
2023
Full Text
View/download PDF

22. Chronic Toxoplasma gondii Infection Modulates Hearing Ability across the Adult Life Span.

Author

Getzmann, Stephan, Golka, Klaus, Bröde, Peter, Reinders, Jörg, Kadhum, Thura, Hengstler, Jan G., Wascher, Edmund, and Gajewski, Patrick D.

Subjects
LIFE spans, TOXOPLASMA gondii, COGNITIVE aging, CONGENITAL disorders, HEARING disorders, AUDIOMETRY
Abstract

While several studies have shown associations between hearing disorders and congenital toxoplasmosis, the present study investigated the impact of chronic, latent Toxoplasma gondii (T. gondii) infection on hearing loss. We used a regression analysis to explore whether latent T. gondii infection modulates changes in hearing thresholds over an age range from 20 to 70 years. We analyzed audiometric data of 162 T. gondii IgG-positive and 430 T. gondii-negative participants, collected in the Dortmund Vital Study (DVS, ClinicalTrials.gov Identifier: NCT05155397), a prospective study on healthy cognitive aging. The regression analysis indicated that latent toxoplasmosis was associated with an accelerated development in hearing loss over the observed age range. Hearing loss was less frequent in IgG-positive than in IgG-negative participants up to the age of about 40 for a low (0.125–1 kHz)-frequency range. For high (2–8 kHz) frequencies, this pattern reversed for ages above 65 years. We discuss these findings on hearing function in the context of a recently proposed model, suggesting that latent toxoplasmosis can differentially affect brain functions across a lifespan. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Cognitive Functions, Neurotransmitter Alterations, and Hippocampal Microstructural Changes in Mice Caused by Feeding on Western Diet

Author

Custodio, Raly James Perez, primary, Hobloss, Zaynab, additional, Myllys, Maiju, additional, Hassan, Reham, additional, González, Daniela, additional, Reinders, Jörg, additional, Bornhorst, Julia, additional, Weishaupt, Ann-Kathrin, additional, Seddek, Abdel-latif, additional, Abbas, Tahany, additional, Friebel, Adrian, additional, Hoehme, Stefan, additional, Getzmann, Stephan, additional, Hengstler, Jan G., additional, van Thriel, Christoph, additional, and Ghallab, Ahmed, additional

Published
2023
Full Text
View/download PDF

26. A Systematic Analysis of Biological, Sociodemographic, Psychosocial, and Lifestyle Factors Contributing to Work Ability Across the Working Life Span: Cross-sectional Study

Author

Gajewski, Patrick D, primary, Rieker, Jennifer A, additional, Athanassiou, Georgios, additional, Bröde, Peter, additional, Claus, Maren, additional, Golka, Klaus, additional, Hengstler, Jan G, additional, Kleinsorge, Thomas, additional, Nitsche, Michael A, additional, Reinders, Jörg, additional, Tisch, Anita, additional, Watzl, Carsten, additional, Wascher, Edmund, additional, and Getzmann, Stephan, additional

Published
2023
Full Text
View/download PDF

27. Correction: Degen et al. Citrinin Exposure in Germany: Urine Biomarker Analysis in Children and Adults. Toxins 2023, 15, 26

Author

Degen, Gisela H., primary, Reinders, Jörg, additional, Kraft, Martin, additional, Völkel, Wolfgang, additional, Gerull, Felicia, additional, Burghardt, Rafael, additional, Sievering, Silvia, additional, Engelmann, Jennifer, additional, Chovolou, Yvonni, additional, Hengstler, Jan G., additional, and Fromme, Hermann, additional

Published
2023
Full Text
View/download PDF

28. Reaching the limits of prognostication in non-small cell lung cancer: an optimized biomarker panel fails to outperform clinical parameters

Author

Grinberg, Marianna, Djureinovic, Dijana, Brunnström, Hans RR, Mattsson, Johanna SM, Edlund, Karolina, Hengstler, Jan G, La Fleur, Linnea, Ekman, Simon, Koyi, Hirsh, Branden, Eva, Ståhle, Elisabeth, Jirström, Karin, Tracy, Derek K, Pontén, Fredrik, Botling, Johan, Rahnenführer, Jörg, and Micke, Patrick

Published
2017
Full Text
View/download PDF

29. Interference with ERK-dimerization at the nucleocytosolic interface targets pathological ERK1/2 signaling without cardiotoxic side-effects

Author

Tomasovic, Angela, Brand, Theresa, Schanbacher, Constanze, Kramer, Sofia, Hümmert, Martin W., Godoy, Patricio, Schmidt-Heck, Wolfgang, Nordbeck, Peter, Ludwig, Jonas, Homann, Susanne, Wiegering, Armin, Shaykhutdinov, Timur, Kratz, Christoph, Knüchel, Ruth, Müller-Hermelink, Hans-Konrad, Rosenwald, Andreas, Frey, Norbert, Eichler, Jutta, Dobrev, Dobromir, El-Armouche, Ali, Hengstler, Jan G., Müller, Oliver J., Hinrichs, Karsten, Cuello, Friederike, Zernecke, Alma, and Lorenz, Kristina

Published
2020
Full Text
View/download PDF

31. Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer

Author

Almstedt, Katrin, primary, Krauthauser, Lisa, additional, Kappenberg, Franziska, additional, Wagner, Daniel-Christoph, additional, Heimes, Anne-Sophie, additional, Battista, Marco J., additional, Anic, Katharina, additional, Krajnak, Slavomir, additional, Lebrecht, Antje, additional, Schwab, Roxana, additional, Brenner, Walburgis, additional, Weikel, Wolfgang, additional, Rahnenführer, Jörg, additional, Hengstler, Jan G., additional, Roth, Wilfried, additional, Hasenburg, Annette, additional, Stewen, Kathrin, additional, and Schmidt, Marcus, additional

Published
2023
Full Text
View/download PDF

32. In vitro to in vivo acetaminophen hepatotoxicity extrapolation using classical schemes, pharmacodynamic models and a multiscale spatial-temporal liver twin

Author

Dichamp, Jules, primary, Cellière, Geraldine, additional, Ghallab, Ahmed, additional, Hassan, Reham, additional, Boissier, Noemie, additional, Hofmann, Ute, additional, Reinders, Joerg, additional, Sezgin, Selahaddin, additional, Zühlke, Sebastian, additional, Hengstler, Jan G., additional, and Drasdo, Dirk, additional

Published
2023
Full Text
View/download PDF

33. Additional file 1 of Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth

Author

Keller, Magdalena, Rohlf, Katharina, Glotzbach, Annika, Leonhardt, Gregor, Lüke, Simon, Derksen, Katharina, Demirci, Özlem, Göçener, Defne, AlWahsh, Mohammad, Lambert, Jörg, Lindskog, Cecilia, Schmidt, Marcus, Brenner, Walburgis, Baumann, Matthias, Zent, Eldar, Zischinsky, Mia-Lisa, Hellwig, Birte, Madjar, Katrin, Rahnenführer, Jörg, Overbeck, Nina, Reinders, Jörg, Cadenas, Cristina, Hengstler, Jan G., Edlund, Karolina, and Marchan, Rosemarie

Abstract

Additional file 1: Supplementary Figure S1. EDI3 is highly expressed in ER-HER2+ cells and is regulated by HER2. A (left panel), HER2 mRNA expression measured using qRT-PCR. Quantification of A (right panel), HER2 and B, ER protein expression from immunoblotting as represented in Figure 1D. C, Immunofluorescence staining, and D, metabolite levels by NMR in a panel of breast cancer cell lines representing the different breast cancer subtypes. E, HER2 and EDI3 mRNA, and F, protein expression in HCC1954 cells upon HER2 silencing. G, EDI3 and HER2 mRNA expression and H, EDI3, pHER2, and HER2 protein expression in SKBR3 cells after silencing EDI3 with siRNA. I, EDI3 and HER2 mRNA expression and J, EDI3, pHER2, and HER2 protein expression in HCC1954 cells after silencing EDI3 with siRNA. K, Representative Western blots showing EDI3, pHER2 and HER2 protein expression in HCC1954 cells treated with 0.1 µM or 1.0 µM lapatinib for 24, 48, 72 and 96h, with corresponding quantification of protein levels. Data are mean ± SD or mean ± SE for HER2 protein expression in panel A of at least three independent experiments (*, P

Published
2023
Full Text
View/download PDF

34. Additional file 3 of Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth

Author

Keller, Magdalena, Rohlf, Katharina, Glotzbach, Annika, Leonhardt, Gregor, Lüke, Simon, Derksen, Katharina, Demirci, Özlem, Göçener, Defne, AlWahsh, Mohammad, Lambert, Jörg, Lindskog, Cecilia, Schmidt, Marcus, Brenner, Walburgis, Baumann, Matthias, Zent, Eldar, Zischinsky, Mia-Lisa, Hellwig, Birte, Madjar, Katrin, Rahnenführer, Jörg, Overbeck, Nina, Reinders, Jörg, Cadenas, Cristina, Hengstler, Jan G., Edlund, Karolina, and Marchan, Rosemarie

Abstract

Additional file 3: Supplementary Figure S3. Effect of targeting EDI3 on viability, alone or in combination with lapatinib, in ER-HER2+ and ER+HER2+ breast cancer cell lines. A-B, EDI3 mRNA (left panels) and protein expression (right panels) after silencing EDI3 using siRNA in A, BT474 and B, EFM192A cells. C, Effect of inhibiting HER2 using increasing concentrations of lapatinib on viability in SKBR3, HCC1954, BT474 and EFM192A cells. D-G Influence of silencing EDI3 with siRNA (oligo #2) and inhibiting HER2 with lapatinib (0.01 µM, 0.1 µM and 1 µM), as well as the combined inhibition of both EDI3 and HER2 on viability in D, SKBR3, E, HCC1954, F, BT474 and G, EFM192A cells. H, Effect of inhibiting HER2 using different concentrations of trastuzumab on viability in SKBR3, HCC1954, BT474 and EFM192A cells. I-L Influence of inhibiting EDI3 with siRNA (oligos #1 and #2) and HER2 with trastuzumab (1 µg/ml and 10 µg/ml), as well as the combined inhibition of both EDI3 and HER2 on viability in I, SKBR3, J, HCC1954, K, BT474 and L, EFM192A. Data are mean ± SD (A-C and H) or mean ± SE (D-G and I-L) of at least three independent experiments (*, P

Published
2023
Full Text
View/download PDF

35. Additional file 2 of Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth

Author

Keller, Magdalena, Rohlf, Katharina, Glotzbach, Annika, Leonhardt, Gregor, Lüke, Simon, Derksen, Katharina, Demirci, Özlem, Göçener, Defne, AlWahsh, Mohammad, Lambert, Jörg, Lindskog, Cecilia, Schmidt, Marcus, Brenner, Walburgis, Baumann, Matthias, Zent, Eldar, Zischinsky, Mia-Lisa, Hellwig, Birte, Madjar, Katrin, Rahnenführer, Jörg, Overbeck, Nina, Reinders, Jörg, Cadenas, Cristina, Hengstler, Jan G., Edlund, Karolina, and Marchan, Rosemarie

Abstract

Additional file 2: Supplementary Figure S2. GSK3β and mTOR are key proteins in HER2-mediated upregulation of EDI3. A, Quantification of HER2, EDI3 and p-Akt protein expression after inhibiting PI3K with 5 and 10 µM LY294002 for 3 and 7 days in MCF7-NeuT cells. B, Representative Western blot and HER2, EDI3 and p-PKCα/βII protein expression quantification after inhibiting PLCγ with 1 and 3 µM U73122 for 3 and 7 days in MCF7-NeuT cells. C, Representative Western blot and quantification of HER2, EDI3 and p-ERK1/2 protein expression after inhibiting MEK with 5 and 25 µM PD98059 for 3 and 7 days in MCF7-NeuT cells. D, HER2, EDI3 and p-mTOR protein expression after inhibiting mTORC1 with 1 and 3 µM everolimus for 3 and 7 days in MCF7-NeuT cells. E, HER2, EDI3 and p-mTOR protein expression after inhibiting mTORC1 with 1 and 3 µM everolimus for 1, 2 and 3 days in HCC1954 cells. F, HER2, EDI3 and p-mTOR protein expression after inhibiting mTORC1 with 1 and 3 µM everolimus for 1, 2 and 3 days in SKBR3 cells. G, HER2, EDI3 and β-catenin protein expression after inhibiting GSKβ with 1 and 2.5 µM CHIR-99021 for 3 and 7 days in MCF7/NeuT cells. H, HER2, EDI3 and β-catenin protein expression after inhibiting GSKβ with 1 and 2.5 µM CHIR-99021 for 1, 2 and 3 days in HCC1954 cells. I, HER2, EDI3 and β-catenin protein expression after inhibiting GSKβ with 1 and 2.5 µM CHIR-99021 for 1, 2 and 3 days in SKBR3 cells. Graphs D-I are quantification of Western blots exemplified in Fig. 3C-H, respectively. J, EDI3 mRNA expression after inhibiting c-Myc with 5 and 10 µM 10074-G5, K, NFκB with 5 and 10 µM SC75741, or L, KLF5 with 5 and 10 µM SR18662 for 1, 2 and 3 days in SKBR3 cells. Data are mean ± SD of at least three independent experiments (*, P

Published
2023
Full Text
View/download PDF

36. Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis

Author

Gui, Wenfang, Hole, Mikal Jacob, Molinaro, Antonio, Edlund, Karolina, Jørgensen, Kristin K., Su, Huan, Begher-Tibbe, Brigitte, Gaßler, Nikolaus, Schneider, Carolin Victoria, Muthukumarasamy, Uthayakumar, Mohs, Antje, Liao, Lijun, Jaeger, Julius, Mertens, Christian J., Bergheim, Ina, Strowig, Till, Hengstler, Jan G., Hov, Johannes R., Marschall, Hanns-Ulrich, Trautwein, Christian, and Schneider, Kai Markus

Subjects
ddc:500
Abstract

Nature Communications 14, 3304 (2023). doi:10.1038/s41467-023-38840-8, Published by Nature Publishing Group UK, [London]

Published
2023
Full Text
View/download PDF

37. Additional file 7 of Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth

Author

Keller, Magdalena, Rohlf, Katharina, Glotzbach, Annika, Leonhardt, Gregor, Lüke, Simon, Derksen, Katharina, Demirci, Özlem, Göçener, Defne, AlWahsh, Mohammad, Lambert, Jörg, Lindskog, Cecilia, Schmidt, Marcus, Brenner, Walburgis, Baumann, Matthias, Zent, Eldar, Zischinsky, Mia-Lisa, Hellwig, Birte, Madjar, Katrin, Rahnenführer, Jörg, Overbeck, Nina, Reinders, Jörg, Cadenas, Cristina, Hengstler, Jan G., Edlund, Karolina, and Marchan, Rosemarie

Abstract

Additional file 7: Supplementary Table S2. List of used reagents including A, QuantiTect primer assays, B, siRNA and shRNA oligos, and C, antibodies.

Published
2023
Full Text
View/download PDF

38. Additional file 6 of Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth

Author

Keller, Magdalena, Rohlf, Katharina, Glotzbach, Annika, Leonhardt, Gregor, Lüke, Simon, Derksen, Katharina, Demirci, Özlem, Göçener, Defne, AlWahsh, Mohammad, Lambert, Jörg, Lindskog, Cecilia, Schmidt, Marcus, Brenner, Walburgis, Baumann, Matthias, Zent, Eldar, Zischinsky, Mia-Lisa, Hellwig, Birte, Madjar, Katrin, Rahnenführer, Jörg, Overbeck, Nina, Reinders, Jörg, Cadenas, Cristina, Hengstler, Jan G., Edlund, Karolina, and Marchan, Rosemarie

Abstract

Additional file 6: Supplementary Table S1. EDI3 (GPCPD1) expression in human breast cancer tissue was evaluated in publicly available Affymetrix HG U133 Plus 2.0 gene expression microarray dataset that were downloaded from the Gene Expression Omnibus webportal (GEO) together with available clinicopathological data.

Published
2023
Full Text
View/download PDF

39. Additional file 8 of Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth

Author

Keller, Magdalena, Rohlf, Katharina, Glotzbach, Annika, Leonhardt, Gregor, Lüke, Simon, Derksen, Katharina, Demirci, Özlem, Göçener, Defne, AlWahsh, Mohammad, Lambert, Jörg, Lindskog, Cecilia, Schmidt, Marcus, Brenner, Walburgis, Baumann, Matthias, Zent, Eldar, Zischinsky, Mia-Lisa, Hellwig, Birte, Madjar, Katrin, Rahnenführer, Jörg, Overbeck, Nina, Reinders, Jörg, Cadenas, Cristina, Hengstler, Jan G., Edlund, Karolina, and Marchan, Rosemarie

Abstract

Additional file 8: Supplementary Table S3. Association of EDI3 expression for the three probesets on the Affymetrix HG U133 Plus 2.0 array and available clinicopathological parameters shown for A, the six datasets combined, as well as separately for B, GSE16446, C, GSE19615, D, GSE28844, E, GSE32646, F, GSE6532, and G, GSE9195. P value from the Mann Whitney or Kruskal-Wallis U test.

Published
2023
Full Text
View/download PDF

40. Additional file 5 of Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth

Author

Keller, Magdalena, Rohlf, Katharina, Glotzbach, Annika, Leonhardt, Gregor, Lüke, Simon, Derksen, Katharina, Demirci, Özlem, Göçener, Defne, AlWahsh, Mohammad, Lambert, Jörg, Lindskog, Cecilia, Schmidt, Marcus, Brenner, Walburgis, Baumann, Matthias, Zent, Eldar, Zischinsky, Mia-Lisa, Hellwig, Birte, Madjar, Katrin, Rahnenführer, Jörg, Overbeck, Nina, Reinders, Jörg, Cadenas, Cristina, Hengstler, Jan G., Edlund, Karolina, and Marchan, Rosemarie

Abstract

Additional file 5: Supplemental Figure S5. Inducibly silencing EDI3 inhibits colony formation and cell viability. A, Representative images (top) and corresponding quantification (bottom) of colony number (left) and size (right) formed by HCC1954 shNEG and HCC1954 shEDI3 (oligos shEDI3 #1, #2, #3) cells treated with 0 or 0.1 µg/ml doxycycline. B, Viability (RFU) after treating HCC1954 shNEG and HCC1954 shEDI3 (oligos shEDI3 #1, #2) with 0.1 or 1 µg/ml doxycycline. All in vitro data are mean ± SD of three independent experiments. (*, P < 0.05; **, P < 0.01; ***, P < 0.001). RFU, relative fluorescence units.

Published
2023
Full Text
View/download PDF

41. Additional file 4 of Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth

Author

Keller, Magdalena, Rohlf, Katharina, Glotzbach, Annika, Leonhardt, Gregor, Lüke, Simon, Derksen, Katharina, Demirci, Özlem, Göçener, Defne, AlWahsh, Mohammad, Lambert, Jörg, Lindskog, Cecilia, Schmidt, Marcus, Brenner, Walburgis, Baumann, Matthias, Zent, Eldar, Zischinsky, Mia-Lisa, Hellwig, Birte, Madjar, Katrin, Rahnenführer, Jörg, Overbeck, Nina, Reinders, Jörg, Cadenas, Cristina, Hengstler, Jan G., Edlund, Karolina, and Marchan, Rosemarie

Abstract

Additional file 4: Supplementary Figure S4. Inhibiting EDI3 with dipyridamole, alone or in combination with HER2-targeting therapy, in ER-HER2+ tumors in mice. A-D EDI3 activity in percent after treatment with dipyridamole at different concentrations in A, HCC1954 B, SKBR3, C, BT474 and D, EFM192 cells. E, Cell viability in percent of vehicle control after treatment with different concentrations of dipyridamole in SKBR3, HCC1954, BT474 and EFM192A cells (upper panel) and EC50-values with corresponding 95% confidence intervals (CI) (lower panel). F, Concentration of dipyridamole in plasma after a single oral dose of 120 mg/kg dipyridamole in mice over time. G, Mouse weight (grams) after treatment with dipyridamole, lapatinib and the combination for up to 4 weeks. H, Images of CD1 nude mice with tumors encircled, after 4-week treatment of vehicle, dipyridamole, lapatinib and the combination of both. I, Plasma and tumor concentrations (µM) of dipyridamole (upper panel) and lapatinib (lower panel) after treatment with each compound alone or in combination (D+L). Data (A-E) are mean ± SD of three independent experiments; mean ± SD of three CD1 mice (F); mean ± SD 5 to 6 mice (G); and representative images of 4 mice per condition H. D+L (combined dipyridamole and lapatinib treatment); BQL (below quantification limit); EC50 (half maximal effective concentration).

Published
2023
Full Text
View/download PDF

45. Prognostic Impact of LAG-3 mRNA Expression in Early Breast Cancer

Author

Heimes, Anne-Sophie, primary, Almstedt, Katrin, additional, Krajnak, Slavomir, additional, Runkel, Anne, additional, Droste, Annika, additional, Schwab, Roxana, additional, Stewen, Kathrin, additional, Lebrecht, Antje, additional, Battista, Marco J., additional, Brenner, Walburgis, additional, Hasenburg, Annette, additional, Gehrmann, Mathias, additional, Hengstler, Jan G., additional, and Schmidt, Marcus, additional

Published
2022
Full Text
View/download PDF

46. Spatial modeling reveals nuclear phosphorylation and subcellular shuttling of YAP upon drug-induced liver injury

Author

Wehling, Lilija, primary, Keegan, Liam, additional, Fernández-Palanca, Paula, additional, Hassan, Reham, additional, Ghallab, Ahmed, additional, Schmitt, Jennifer, additional, Tang, Yingyue, additional, Le Marois, Maxime, additional, Roessler, Stephanie, additional, Schirmacher, Peter, additional, Kummer, Ursula, additional, Hengstler, Jan G, additional, Sahle, Sven, additional, and Breuhahn, Kai, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results